No Data
No Data
Satellos Announces Participation in September 2024 Investor Conferences
Satellos Bioscience Given Go-ahead for Phase 1 Clinical Trial With SAT-3247 in Australia
Satellos Bioscience Brief: Adds "On Track: to Dose First Participant in Phase 1 Clinical Trial With SAT-3247 in Q3 2024; Cites Cash Balance of $27.7 Million at June 30, 2024
Satellos Bioscience Brief: Cites Receipt of Orphan Drug and Rare Pediatric Disease Designations From US FDA
Satellos Bioscience Brief: Says Updated Data in a Canine Model of Duchenne Muscular Dystrophy (DMD) Show Further Increased Improvement in Muscle Force Over Baseline of 195% at Four-month Point
Satellos Bioscience Inc. Brief: Reporting a Q2 Net Loss of $6.0 Million ($0.05 Loss per Share)
No Data